Similar articles for PMID: 36282125

Year	Number of Results
2017	2
2018	4
2019	20
2020	29
2021	34
2022	24
2023	3

1

Prognostic biomarkers correlated with immune infiltration in non-small cell lung cancer.

Xu F, Cui WQ, Liu C, Feng F, Liu R, Zhang J, Sun CG. Xu F, et al. FEBS Open Bio. 2023 Jan;13(1):72-88. doi: 10.1002/2211-5463.13501. Epub 2022 Nov 28. FEBS Open Bio. 2023. PMID: 36282125 Free PMC article.

2

Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.

Shi Y, Lei Y, Liu L, Zhang S, Wang W, Zhao J, Zhao S, Dong X, Yao M, Wang K, Zhou Q. Shi Y, et al. Cancer Med. 2021 Apr;10(7):2216-2231. doi: 10.1002/cam4.3649. Epub 2021 Mar 2. Cancer Med. 2021. PMID: 33655698 Free PMC article.

3

Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancers.

Hu C, Zhao L, Liu W, Fan S, Liu J, Liu Y, Liu X, Shu L, Liu X, Liu P, Deng C, Qiu Z, Chen C, Jiang Y, Liang Q, Yang L, Shao Y, He Q, Yu D, Zeng Y, Li Y, Pan Y, Zhang S, Shi S, Peng Y, Wu F. Hu C, et al. J Immunother Cancer. 2021 Dec;9(12):e003773. doi: 10.1136/jitc-2021-003773. J Immunother Cancer. 2021. PMID: 34887263 Free PMC article.

4

Prognostic and Immunological Role of FAT Family Genes in Non-Small Cell Lung Cancer.

Feng Z, Yin Y, Liu B, Zheng Y, Shi D, Zhang H, Qin J. Feng Z, et al. Cancer Control. 2022 Jan-Dec;29:10732748221076682. doi: 10.1177/10732748221076682. Cancer Control. 2022. PMID: 35212236 Free PMC article.

5

[Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].

Jin Y, Chen YM, Hu X, Tang HR, Yu XM, Fan Y, Xu YJ, Xu HM, Li PS, Li Q, Chang LP, Guan YF, Chen M. Jin Y, et al. Zhonghua Yi Xue Za Zhi. 2020 Dec 8;100(45):3614-3621. doi: 10.3760/cma.j.cn112137-20200504-01412. Zhonghua Yi Xue Za Zhi. 2020. PMID: 33333686 Chinese.

6

M6A regulator expression patterns predict the immune microenvironment and prognosis of non-small cell lung cancer.

Liu X, Ma C, Liu H, Sun Z, Luo J. Liu X, et al. J Cancer Res Clin Oncol. 2022 Oct;148(10):2803-2814. doi: 10.1007/s00432-022-04032-y. Epub 2022 May 20. J Cancer Res Clin Oncol. 2022. PMID: 35596010

7

Co-Mutation of FAT3 and LRP1B in Lung Adenocarcinoma Defines a Unique Subset Correlated With the Efficacy of Immunotherapy.

Zhu M, Zhang L, Cui H, Zhao Q, Wang H, Zhai B, Jiang R, Jiang Z. Zhu M, et al. Front Immunol. 2022 Jan 6;12:800951. doi: 10.3389/fimmu.2021.800951. eCollection 2021. Front Immunol. 2022. PMID: 35069585 Free PMC article.

8

Multidimensional profiling depicts infiltrating immune cell heterogeneity in the tumor microenvironment of stage IA non-small cell lung cancer.

Duan J, Lv G, Zhu N, Chen X, Shao Y, Liu Y, Zhao W, Shi Y. Duan J, et al. Thorac Cancer. 2022 Apr;13(7):947-955. doi: 10.1111/1759-7714.14329. Epub 2022 Feb 11. Thorac Cancer. 2022. PMID: 35150094 Free PMC article.

9

Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.

Yu Y, Zeng D, Ou Q, Liu S, Li A, Chen Y, Lin D, Gao Q, Zhou H, Liao W, Yao H. Yu Y, et al. JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879. JAMA Netw Open. 2019. PMID: 31290993 Free PMC article.

10

Genomic features of Chinese small cell lung cancer.

Liu J, Zhao Z, Wei S, Li B, Zhao Z. Liu J, et al. BMC Med Genomics. 2022 May 20;15(1):117. doi: 10.1186/s12920-022-01255-3. BMC Med Genomics. 2022. PMID: 35596192 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed